Dermavant Sciences: Dermavant to Present New Data from Phase 3 Trial Program of VTAMA (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress
- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing